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Abstract
The use of stimulants (methylphenidate and amphetamine) as cognitive enhancers by the general public is increasing and is
controversial. It is still unclear how they work or why they improve performance in some individuals but impair it in others.
To test the hypothesis that stimulants enhance signal to noise ratio of neuronal activity and thereby reduce cerebral activity
by increasing efficiency, we measured the effects of methylphenidate on brain glucose utilization in healthy adults. We
measured brain glucose metabolism (using Positron Emission Tomography and 2-deoxy-2[18F]fluoro-D-glucose) in 23
healthy adults who were tested at baseline and while performing an accuracy-controlled cognitive task (numerical
calculations) given with and without methylphenidate (20 mg, oral). Sixteen subjects underwent a fourth scan with
methylphenidate but without cognitive stimulation. Compared to placebo methylphenidate significantly reduced the
amount of glucose utilized by the brain when performing the cognitive task but methylphenidate did not affect brain
metabolism when given without cognitive stimulation. Whole brain metabolism when the cognitive task was given with
placebo increased 21% whereas with methylphenidate it increased 11% (50% less). This reflected both a decrease in
magnitude of activation and in the regions activated by the task. Methylphenidate’s reduction of the metabolic increases in
regions from the default network (implicated in mind-wandering) was associated with improvement in performance only in
subjects who activated these regions when the cognitive task was given with placebo. These results corroborate prior
findings that stimulant medications reduced the magnitude of regional activation to a task and in addition document a
‘‘focusing’’ of the activation. This effect may be beneficial when neuronal resources are diverted (i.e., mind-wandering) or
impaired (i.e., attention deficit hyperactivity disorder), but it could be detrimental when brain activity is already optimally
focused. This would explain why methylphenidate has beneficial effects in some individuals and contexts and detrimental
effects in others.
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Introduction
Stimulant medications such as methylphenidate (MP) are used
extensively in the treatment of Attention Deficit Hyperactivity
Disorder (ADHD) to decrease symptoms of inattention[1] Also, in
certain conditions (e.g., sleep deprivation), MP may improve
attention and performance of individuals without ADHD[2].
Indeed the past decade has seen an increase in the use of stimulant
medications as cognitive enhancers that is of increasing concern
both because of their side effects as well as their potential for abuse
and addiction[3,4].
The biochemical mechanisms of action of MP have been well
characterized: it increases extracellular levels of dopamine and
norepinephrine by blocking the respective monoamine transport-
ers[5]. It is unclear how these actions relate to its effects in
attention and performance. Since dopamine and norepinephrine
decrease background firing rates of neuronal cells increasing
signal-to-noise ratio[6,7], we hypothesized that in humans MP’s
dopaminergic and noradrenergic effects by decreasing non-task
related activity should reduce the amount of glucose utilized by the
brain while performing a cognitive task.
We measured regional brain glucose metabolism in 23 healthy
subjects when they performed a mathematical task with difficulty
controlled to achieve 80% accuracy. The difficulty-controlled task
was performed after administration of placebo and after
administration of MP (20 mg, oral), and these conditions were
compared to a control condition, which consisted of viewing
nature cards with not performance required (non-task condition)
after being given a placebo. In addition, 16 of the subjects were
tested in a fourth condition (non-task condition after being given
MP) (Figure 1).
Results
PET imaging documented that the cognitive task significantly
increased whole brain metabolism when compared with the
control condition both when given with placebo and with MP.
Whole brain metabolism differed significantly for the conditions
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min) and the neutral non-task condition preceded by MP
(35.865 mmol/100 g/min) than for the cognitive task with
placebo (43.267 mmol/100 g/min) or the cognitive task preceded
by MP (40.367 mmol/100 g/min). The increase in whole brain
metabolism was significantly smaller when the cognitive task was
preceded by MP, than when preceded by placebo (11622% versus
21626%; p,0.01). Individual analysis of the responses revealed
that 16 of the 23 subjects had less activation with MP than with
placebo when performing the task, 5 had greater activation with
MP than with placebo and 2 did not differ (Chi-Square p,0.02)
(Table 1).
Correlation analysis between the differences in brain activation
when the task was given with placebo versus MP showed a
significant correlation with baseline metabolism (r=0.48, p,0.05);
the lower the metabolism at baseline the greater the attenuation of
the activation by the task by MP. The difference in brain
activation when the task was given with placebo versus MP was
also significantly correlated with the activation to the task with
placebo (r=0.57, p,0.005) but not with activation to the task with
MP (r=0.02, NS) indicating that the response to MP was
dependent both on metabolism at baseline and on the level of
activation by the task when given without a pharmacological
challenge.
There were no differences in money made (surrogate marker of
performance) when the cognitive task was done with placebo
($47.6064) versus when it was done with MP ($48.8063).
However there was significant intersubject variability: 7 subjects
made more money with MP, 4 made less money and 12 made the
same amount as with placebo. Correlation analysis between the
differences in money earned when performing the cognitive task
with MP versus placebo and the metabolic differences in activation
between these two conditions were significant in paracentral lobule
(r=0.50, p,0.02), superior (r=0.50, p,0.02) and inferior parietal
cortices (r=0.43, p,0.05), dorsal (r=0.45, p,0.05) and posterior
CG/precuneus (r=0.44, p,0.05). The greater the attenuation the
larger the amount of money made with MP.
The smaller task-related increase in brain consumption of
glucose with MP was related to focusing of brain activity. This is
shown on the statistical parametric (SPM) analysis, which revealed
that the area of significant activation (p,0.001) with the cognitive
task was much larger with placebo (67,985 pixels) than with MP
(22,632 pixels) (Figure 2). The cognitive task for both conditions
(placebo and MP) increased metabolism in left frontal, left parietal,
occipital, and cerebellar regions; however when given with
placebo, the task additionally increased metabolism in right
frontal, right parietal, anterior cingulate, and left thalamic regions
(Figure 2). The SPM comparison between the two cognitive task
conditions corroborates these differences showing significantly
greater activation in frontal, parietal, cingulate, thalamus and
hippocampus when the cognitive task was given with placebo than
with MP (Figure 3). Independently drawn region of interest
analysis revealed similar findings (Table 2).
In contrast to the differences between placebo and MP when
given with the cognitive task there were no differences in brain
metabolism when MP was given with the neutral non-task
condition (whole brain metabolism: 35.865 mmol/100 g/min)
when compared with the neutral non-task condition when given
with placebo (36.666 mmol/100 g/min). The SPM analysis
corroborated this and revealed no significant differences when
the neutral non-task condition was given with placebo (control
condition) versus when it was given with MP (data not shown).
Discussion
This study documents that when MP was given with a cognitive
task it markedly attenuated the brain metabolic increases induced
by the task and reduced the regions activated by it. The reduction
in activation with MP included the parietal cortex, cingulate gyrus
and thalamus, which are regions involved in the orienting,
executive, and alerting attentional networks respectively[8]. Thus,
we interpret our findings to indicate that compared to placebo MP
reduced (focused) the use of attentional resources in the human
brain that are necessary to achieve similar levels of performance
on a task.
These findings are consistent with those of prior imaging studies
showing reductions with MP in the increases in cerebral blood
flow (CBF) in dorsolateral prefrontal and posterior parietal cortices
when healthy controls performed a working memory task[9] and
in prefrontal cortex when adults with ADHD performed a task of
executive function[10]. However, the MP-related attenuation of
CBF increases by the task in these studies was much more
restricted (focused to discrete brain regions) than the large and
extensive attenuation in whole brain metabolism we report using
Figure 1. Schematic diagram of experimental procedure.
Placebo (PL) or methylphenidate (MP) was given 60 minutes prior to
initiation of Cognitive or Neutral tasks, which lasted 45 minutes.
[
18F]FDG was injected 15 minutes after task initiation (75 minutes after
MP or PL) and scans were started 35 minutes after injection.
doi:10.1371/journal.pone.0002017.g001
Table 1. Differences in brain metabolic activation to the task (percent change) when given with MP when compared with placebo
(PL) between subjects in whom MP attenuated brain activation versus those in whom it enhanced activation along with their
baseline metabolic measures.
Attenuated Response with MP Enhanced Response with MP Difference
Number Ss 16 5 p,0.02
% Brain PL v MP 216614 +761 p,0.004
Baseline metabolism 3564 mmol/100 g/min 3967 mmol/100 g/min p,0.09
Two subjects showed no differences between MP and placebo (data not included). Comparisons correspond to chi square for the subject numbers (Ss) and to student t-
tests (unpaired, two test) for the other comparisons.
doi:10.1371/journal.pone.0002017.t001
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18F]FDG. Glucose metabolism may offer an advantage because it
is a more proximal measure of neuronal activity than CBF[11].
Moreover, regional CBF may become uncoupled from metabo-
lism during stimulation[12,13].
Synaptic levels of DA and NE, which are increased by MP[5],
under physiological conditions act primarily as neuromodulators
changing the efficacy of other transmitter signals[14,15] as a
function of ongoing neuronal activity[16]. For example, in
striatum, applications of DA decrease the activity of spontaneously
active neurons to a greater extent than that of glutamate-
stimulated neurons[6]. This increase in glutamate-induced exci-
tation relative to baseline is assumed to improve signal-to-noise
neuronal activation[17]. Norepinephrine can also facilitate
excitatory transmission by depressing the level of basal activi-
ty[18]. The greater decreases in spontaneous neuronal firing (basal
activity) than in task relevant neuronal responses from MP’s
dopaminergic and noradrenergic effects could therefore explain
the reduction in the metabolic increases (as well as CBF decreases)
induced by the cognitive task. In addition the global effects in
metabolism that we observed with MP while performing the task
may reflect downstream effects of increasing signal to noise in
regions processing the task into regions whose background activity
covary with that of regions activated by the task[19].
The dependency of DA and NE effects as a function of the
ongoing neuronal activity[17] could explain the differential
response to MP we observed across the neutral and cognitive task
conditions (i.e., no effect when given with a neutral non-task but
attenuation of increases in metabolic activation when given with a
cognitive task). Similar results were reported for MP effects on
CBF; decreases in task related activation but no changes with the
control condition[9]. The task dependency of MP effects is
consistent with clinical findings documenting that the effects of
stimulant medications are context dependent[20,21].
It is worth noting that while most individuals showed lower
metabolic activation during the cognitive task with MP than with
placebo (16 of 23), five subjects showed greater activation with MP
than with placebo and 2 subjects did not change. Because only 5
Figure 2. Brain activation with the task after placebo (PL) and after methylphenidate (MP). A. SPM results showing the areas that had
increases in metabolism for the cognitive task with placebo versus the control conditions; B. SPM results showing the areas that had increases in
metabolism for the cognitive task with MP versus the control conditions. Comparisons correspond to paired t tests (p,0.001 uncorrected
.100 pixels). None of the brain regions had higher metabolism for the control condition (neutral non-task with placebo) than for the cognitive task
conditions.
doi:10.1371/journal.pone.0002017.g002
Figure 3. Differences in task activation between placebo (PL)
and methylphenidate (MP). SPM results showing the areas that had
greater increases in metabolism when the cognitive task was given with
p l a c e b ov e r s u sw h e ni tw a sg i v e nw i t hm e t h y l p h e n i d a t e( M P ) .
Comparisons correspond to paired t-tests (p,0.005 uncorrected
.100 pixels). None of the brain regions had higher metabolism for
the cognitive task when given with MP than with placebo.
doi:10.1371/journal.pone.0002017.g003
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sufficient power to assess if there were differences in baseline brain
metabolism or in brain activation to the task between the group of
subjects in whom MP decreased versus those in whom it enhanced
activation. However, the correlation analysis revealed that the
difference in activation between MP and placebo during the
cognitive task was correlated both with baseline brain metabolism
(control condition) and with the brain activation to the task when
preceded by placebo. That is, subjects in whom MP produced the
largest attenuation in activation to the task were the ones that had
lower brain metabolism at baseline but also had the largest brain
metabolic increases when the cognitive task was given with
placebo. Subjects with minimal activation to the task were the ones
in whom MP produced the least change and were also the ones
that did not improve performance with MP (assessed by monetary
earnings). This is consistent with the notion that those individuals
who already have ‘‘optimal focusing’’ of brain resources would
show no benefit from MP. The dependency of MP effects to the
magnitude of activation to the task (when given with placebo) is
also consistent with idea that the effects of MP in a given subjects
are rate dependent; that is determined by their baseline level of
performance[22,23].
The correlation analysis between the difference in money
between the cognitive task with MP versus with placebo and the
differences in metabolic activation between these two conditions
was significant in the paracentral lobule (BA 5), dorsal and
posterior CG/precuneus (BA 23, 29, 30, 7) and in parietal cortex
(BA 39, 40, 7); subjects in whom MP induced the largest
Table 2. Regional glucose metabolism (mg/100 g/min) when subjects were tested during the neutral non-task with placebo
(control condition), cognitive task with MP and cognitive task with placebo.
Frontal Cortex Control Condition Cognitive task with MP Cognitive task with PL Cognitive Task MP v PL
Left Right Left Right Left Right Left Right
Parietal
BA 5 39.167 40.067 43.267
a 42.768 47.768
c 47.768
c 0.001 0.001
BA 7 45.267 44.668 50.169
b 50.069
a 55.869
d 54.469
d 0.002 0.005
BA 39 44.166 43.767 49.269
a 46.969 52.769
c 51.169
c 0.02 0.002
BA 40 44.567 44.868 50.0610
a 49.0610
a 53.569
d 53.469
d 0.01 0.004
Frontal
BA 6 44.067 44.667 50.469
c 49.969
a 54.769
d 54.869
d 0.005 0.003
BA 8 45.168 47.569 48.469 51.0610 52.968
c 56.269
c 0.002 0.003
BA 9 42.467 44.367 46.669
a 48.469
a 50.168
c 52.368
c 0.008 0.007
BA 11 41.667 42.367 43.469 43.568 44.067 44.168 0.64 0.66
Anterior CG
BA 24 37.066 36.966 40.168 39.968 43.968
c 43.268
c 0.003 0.02
BA 32 40.967 42.868 45.168
a 47.669
a 48.568
c 50.169
d 0.008 0.02
Temporal
BA 13 38.267 37.5267 41.868 39.968 44.568
b 42.667
b 0.03 0.02
BA 22 43.166 45.466 47.868
a 49.168 50.868
c 52.069
c 0.03 0.03
Occipital
BA 17 49.4610 51.2610 61.0612
d 63.4610
d 64.9613
d 67.6612
d 0.03 0.05
BA 18 48.268 47.568 55.869
d 55.5610
d 59.3610
d 59.0610
d 0.02 0.03
BA 19 45.067 44.067 49.969
a 48.168
a 52.969
c 51.268
c 0.03 0.03
Limbic
Hippocampus 23.465 23.665 25.364 24.065 27.665
a 27.065
a 0.04 0.03
Amygdala 27.766 26.066 30.666 28.167 33.366
b 31.967
a 0.006 0.02
Striatum
Caudate 40.368 34.968 43.1610 36.167 46.1610
a 40.269
a 0.05 0.003
Putamen 42.867 40.567 45.769 43.169 49.468
b 46.768
b 0.009 0.008
Thalamus
Medio dorsal 44.561 40.969 51.4612
b 47.5610
c 54.4611
c 50.069
c 0.10 0.07
Ventro Lateral 30.767 35.668 34.267
a 40.768
c 38.268
c 43.269
c 0.002 0.08
Ventro Post Lat 29.767 36.667 32.865
a 41.668
b 37.367
c 44.869
c 0.004 0.03
Ventro Post Md 41.268 44.267 46.667
c 52.5611
d 51.569
d 56.2611
d 0.01 0.05
Cerebellum 35.165 35.065 40.167
c 40.067
c 41.867
c 41.467
c 0.19 0.25
Data corresponds to mean and standard deviation. Subscripts correspond to paired t-test comparisons with respect to the control condition:
ap,0.05,
b p,0.01,
c p,0.005,
d p,0.001. The last column corresponds to the significance level for comparison between the cognitive task when given with MP or
when given with placebo (PL).
doi:10.1371/journal.pone.0002017.t002
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with placebo. The dorsal and posterior CG, the paracentral lobule
and the inferior parietal cortices are regions that form part of the
default network, which is deactivated when performing a task[24]
and activated during mind-wandering (BA 31, 29, 30)[25]. Thus
one could speculate that the ability of MP to decrease the
activation in the default network and to decrease mind-wandering
is one of the mechanisms that accounts for its beneficial effects in
subjects in whom it improves performance. However, in
individuals in whom the default network is already optimally
deactivated during the task, MP may deteriorate performance as
was the case for the 4 subjects in our study who made less money
with MP than with placebo.
Though it was once assumed that the beneficial effects of
stimulant medications (including MP) on individuals with ADHD
were paradoxical, studies have demonstrated that the direction of
response is the same in healthy individuals without ADHD[26].
This confusion may reflect in part the fact that the responses to
stimulant medications are dependent on the initial level of
performance; typically performance is improved only when
cognitive processing is below optimal, resulting in a non-monotonic
(U-shaped) function[27]. Our findings suggest a neural mechanism
for this: we postulate that when neuronal resources are widely
distributed across brain regions, the action of MP to focus (reduce)
regional activation would improve performance on a specific task,
whereas the MP-related restriction of regional brain activation
when already optimally deployed could impair performance.
The oral dose of MP used in this study (20 mg) is within the
range used therapeutically for the treatment of ADHD in adults.
The lack of an effect on brain metabolism with the neutral non-
task suggests that this dose of MP without a concomitant cognitive
activation does not affect brain activity. This is consistent with our
prior findings showing that 20 mg of oral MP did not significantly
increase DA in the striatum (assessed with PET and [
11C]raclo-
pride) when given with a neutral non-task whereas it increased it
when MP was administered concomitantly with a cognitive task
(same numerical calculations task used for the current study)[28].
It is also consistent with prior imaging studies showing minimal
changes in regional brain glucose metabolism in ADHD subjects
given MP without stimulation[29].
Limitations for this study include the fact that the assessment of
brain glucose metabolism with PET and FDG reflects the average
activityofthebrainovera30 minuteperiod,whichdoesnotallowan
assessment of the dynamic changes that may occur during that time
period. Our experimental design did not allow us to evaluate the
relationship between the inter-subject variability in the brain
metabolic responses to MP during the task and an individual’s level
of performance. In our design, the difficulty of the task was adjusted
so that each subject would achieve a constant level of performance
(about 80% accuracy), and the adjustments varied across individuals
since they depended on each individual’s level of ability on the
mathematical task as well as his/her ability for the different
mathematical operations. Also in this study the amount of money
made during the task (a possible indicator of a subject’s overall
performance) was constrained by the adjustment procedures. In
future studies, different designs with more precise measures of
performance could be used to evaluate the extent to which the
differences between subjects and within subjects in response to MP
relate to difference in their performance capacity and how this
informationcanbeusedtopredictresponsetostimulantmedications.
Summary
This study shows that compared to placebo, an oral dose of
MP reduced the brain metabolic increases associated with
performance of a cognitive task. Inasmuch as the brain required
about 50% less increase in glucose to perform the task at the same
level of performance, this provides evidence that one of the
mechanisms of action of MP is to focus activation and make the
brain more efficient.
Our study of the effects of MP on brain function in healthy
adults may contribute to theoretical basis for how and when
stimulant drugs may (or may not) enhance attention and
performance. To the extent that neuronal resources are non-
optimally distributed, reduced task-induced regional activation
could result in improved performance. Non-optimal distribution of
attentional resources may occur in some individuals (ie., those with
ADHD) or in healthy individuals after sleep deprivation. However,
if neuronal resources are already optimally deployed, further
focusing of neuronal activity could result in stimulant-related
deterioration of performance.
Materials and Methods
Subjects
Twenty three healthy controls (12 M and 11 F; 3267 years of
age) who responded to an advertisement were studied. Subjects
were initially screened by phone and then evaluated at
Brookhaven National Laboratory by a physician for exclusion
criteria, which included current or past psychiatric disorder
(including drug abuse or dependence), neurological disease,
significant medical illness, current treatment with medication
(including over the counter drugs) and pregnancy. Normal
physical examination and laboratory tests were required for entry.
Pre-scan urine tests ensured the absence of any psychoactive drugs
and of pregnancy in females. Subjects were monetarily compen-
sated for their participation. Written informed consent was
obtained in all subjects in accordance with the local Institutional
Review Board.
Scans
PET scans were obtained with a whole-body, high-resolution
positron emission tomograph (Siemens/CTI ECAT HR+, with
4.664.664.2 mm NEMA (National Electrical Manufacturers
Association) resolution at center of field of view and 63 slices) in
3D dynamic acquisition mode using [
18F]FDG. Details about the
methods for scanning have been published[30]. Briefly, a
20 minute emission scan was started 35 minutes after injection
of 4–6 mCi of [
18F]FDG. Arterialized blood sampling was used to
measure FDG in plasma.
All subjects were scanned 3 times with [
18F]FDG under the
following conditions: 1. Neutral non-task preceded by placebo,
which was the ‘‘control’’ condition; 2. Cognitive task preceded by
MP; 3. Cognitive task preceded by placebo. In addition, 16 of the 23
subjects underwent a fourth [
18F]FDG scan conducted with the
neutral non-task preceded by MP. Each scan was performed on a
separate day and subjects were blinded as to whether they received
MP(20 mgpo)orplacebo.Theorderoftheconditionswasbalanced
across subjects. Venous blood was drawn to quantify plasma
concentrations of MP prior to and at 60, 90 and 120 minutes after
MP using capillary GC/Mass spectrometry[31]. Plasma concentra-
tions did not differ between conditions and averaged 6.562n g / m L
between 90–120 minutes after administration.
Tasks
For the cognitive task the subjects were first assessed on their
numerical abilities using numerical problems grouped into 5 levels
of difficulty. The level at which each individual responded
correctly to 80% of the problems was selected for the testing
MP Improves Brain’s Efficiency
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multiplications or divisions) were presented on colored cards
(one card per minute). Within individuals, problem difficulty was
adjusted dynamically based on each individual’s cumulative
performance to try to maintain a constant level of performance
across individuals and conditions (with a target of 80% accuracy).
Correct responses were remunerated by 25 cents to one dollar
depending on the difficulty of the question. The total amount
made at the end of the session was quantified and used as
surrogate for performance. For the neutral non-task, subjects were
shown cards with pictures of scenery but were not asked to provide
responses nor were they remunerated. The tasks were started
15 minutes prior to radiotracer injection (60 minutes after placebo
or MP) and were continued for 45 minutes (Figure 1).
Image and data Analysis
The data were analyzed both using regions of interest (ROI) and
Statistical Parametric Mapping (SPM)[32].
For SPM analysis, the metabolic images were spatially
normalized using the template provided in the SPM 99 package
and subsequently smoothed with a 16 mm isotropic Gaussian
kernel. Paired samples t-tests were performed for the following
comparisons: 1. control condition versus cognitive task with MP; 2.
Control condition versus cognitive task with placebo; 3. cognitive
task with MP versus cognitive task with placebo; and 4. control
condition versus neutral non-task with MP (this comparison was
for 16 subjects). Significance was set at p,0.001 (uncorrected,
.100 voxels) for the comparisons against the control condition
and to p,0.005 for the comparisons between the two cognitive
task conditions. Statistical maps were overlaid on an MRI
structural image.
For ROI analysis, we extracted independently drawn ROI using
an automated extraction method that is based on the standard
brain template from the Talairach atlas[33]. First, to eliminate
variations across individuals’ brains, the [
18F]FDG images were
mapped into the Talairach brain using the spatial normalization
package in SPM. The inverse mapping procedure was used to
extract the Talairach coordinates of all voxels for a given
anatomical region using the stereotactic coordinates in the
Talairach Daemon database[34,35]. These anatomically defined
ROIs were overlapped voxel-by-voxel onto the SPM normalized
PET image.
To compare the metabolic values in the ROI we used a
repeated measure ANOVA for the 3 conditions for which we had
measures in all subjects (control condition, cognitive task with MP
and cognitive task with placebo). Post hoc t-tests were used to
assess which conditions differed. In the 16 subjects for whom the
neutral non-task with MP condition was obtained we used a paired
t-test to compare it with the control condition. Because of the
multiplicity of comparisons to protect against type 1 error we set
the level of significance to p,0.005; we did not use Bonferroni
correction since it assumes independence between measures
whereas the regional metabolic measures are not independent
from one another. Also we only consider significant findings that
were corroborated both by SPM and ROI analysis. We also
analyzed the individual responses and used chi-square analysis to
compare the number of subjects in whom MP attenuated the
metabolic increases to the task (.2.5%) versus the number of
subjects in whom MP enhanced them.
Pearson product moment correlations were performed to assess
if the differences in brain activation with the cognitive task
(placebo versus MP) were associated with: (1) baseline brain
metabolism, (2) brain activation when the task was given with
placebo, or (3) brain activation when the task was given with MP.
We also performed correlation analysis to assess the relationship
between the difference in regional activation during the cognitive
task when given with placebo versus MP and the difference in the
money earned between both conditions (used as surrogate marker
of performance).
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